BLASTNCT07893509
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (4)
Arms and interventions
Patients with Intermediate Risk non-muscle invasive bladder cancer
Non-Muscle I invasive Bladder Cancer who have never received BCG, or patients who had a complete response to BCG and relapsed more than 24 months after their last BCG dose.
Includes: * BCG-resistant NMIBC: Persistent or recurrent high-grade Ta or CIS disease at 3mo evaluation after at least 5/6 doses induction BCG. * Delayed relapse after inadequate BCG: Although maintenance BCG should always follow successful induction BCG according to the guidelines, many patients only receive induction without maintenance. Disease-free at the 3mo evaluation, so the earliest relapse would be 6mo after initial diagnosis. Latest relapse that would be considered would be a high-grade recurrence 24mo after initial diagnosis. * Delayed relapse after adequate BCG: Disease-free after induction and at least one course of maintenance BCG (or second round of induction BCG), but subsequently experience a high-grade recurrence outside of the BCG-unresponsive window (\>6mo for Ta/T1 and \>12mo for CIS). Since a high-grade relapse beyond 24mo after the last dose of BCG would probably respond well to BCG again, this disease state would include only patients with relapse up to 24mo.
Patients meeting the definition of BCG-unresponsive disease. Patients with HR NMIBC, "Adequate" induction + maintenance BCG (mBCG): at least 5/6 doses induction, plus at least 2/3 doses maintenance or at least 5/6 doses reinduction Categories of patients to include in BCG unresponsive arm: 1. \- patients with ≥ T1 HG disease on the first assessment following adequate induction BCG 2. \- patients with ≥ Ta HG disease within 6 months of adequate induction + maintenance BCG 3. \- patients with any component of CIS within 12 months of adequate induction + maintenance BCG 4. \- Any patient previously meeting criteria for BCG unresponsiveness who has a recurrence will be eligible for trial in category of BCG unresponsiveness even if last BCG was more than 1 year ago.
Muscle Invasive Cancer who receive ctDNA profiling over time in addition to receiving standard of care, which includes a radical cystectomy. This group includes those who choose adjuvant therapy and those who do not.
Other: This is a non-interventional, observational, prospective study.
Sites
1 site in 1 country
- UT Southwestern Medical CenterDallas, Texas, United States